Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Peripheral Blood Smears Still Need Evaluation

By LabMedica International staff writers
Posted on 22 Jun 2017
When the first automated hematology analyzers appeared in clinical laboratories in the 1960s, they ushered in a welcomed workflow change for bench technologists. More...
These automated analyzers replaced hemocytometers, though the need for differential counting remained.

This evolution in hematology workflows has continued to this day, with automated instruments performing ever more cellular analysis, resulting in more focused roles for technologists and pathologists. However, certain characteristics of peripheral blood morphology still do not lend themselves easily to evaluation by automated analyzers.

A clinical associate professor at the University of Florida (Gainesville, FL, USA) has written that one limitation that has remained constant from the earliest hematology analyzers to today’s cutting-edge flow cytometers is that a single cell still must pass through an aperture for analysis. In order to maintain laminar flow, the cell must also be sphered, which is most often accomplished with a proprietary sphering reagent. The exact classification of abnormally shaped red cells, for example, sickle cells, target cells, and schistocytes, still requires morphologic review of stained slides.

In addition red cell and white cell inclusions, particularly infectious organisms such as malaria or histoplasmosis, can be seen in stained blood smears but are not routinely detected by most automated hematology analyzers. Because of the extensive morphologic variability of many circulating hematologic malignancies, automated systems cannot precisely characterize these cells. Most analyzers, however, aid in characterizing these cells by pre-classifying them as abnormal (through large unstained cell classification or flagging) and prompting manual review of slides.

Analyzers that have digital morphology capabilities, such as the CellaVision or the Bloodhound systems, are inaugurating a new era of cellular analysis. As these instruments’ algorithms continue to be refined, this technology might evolve from a pre-classifier method to a more enhanced and robust method for precise characterization. The accuracy of an automated differential count depends on the analytical system used. However, given that most automated counters literally characterize thousands of white cells for each analysis, the classic 100-cell manual differential count in comparison falls short when it comes to precision. Sherri D. Flax, MD, published her article on June 1, 2017, in the journal Clinical Laboratory News.

Related Links:
University of Florida


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.